Informed Consent in Psychedelic Research and Care

Why consent is a special question here

Informed consent means a person understands the main benefits, risks and alternatives and agrees freely. Psychedelic treatment strains this in several ways: the experience can change perception, cognition and judgment for many hours, it is hard to describe beforehand, and the person is in a vulnerable state during treatment. This page is information only and gives no advice about using any substance.

Evidence label used here: where a point is an ethicists' argument rather than a test result, we say so. Where nothing usable was found we write "Proper evidence not found".

What the FDA expects consent to say

For trials under an FDA research application, the FDA's guidance says informed consent should clearly describe that participants may experience changes in perception, cognition and judgment that persist for many hours, as well as increased vulnerability and suggestibility during the treatment session. [1]

Seven elements one expert analysis lists

A 2024 JAMA Psychiatry analysis argues that consent for psychedelic medicine needs seven essential components: the possibility of short- and long-term perceptual disturbances; potential personality changes and altered metaphysical beliefs; the limited role of reassuring physical touch; the potential for patient abuse or coercion; the role and risks of data collection; relevant practitioner disclosures; and interactive patient education with a comprehension check. [2] The authors report that publicly available consent documents for psychedelic trials often overlook or underemphasize these elements, and that no government had approved any classic psychedelic for general medical use when they wrote. [2] Treat this as a well-argued expert proposal, not as an established standard.

Can anyone fully consent in advance?

Ethicists disagree.

• One argument holds that the experience and its after-effects are "epistemically inaccessible" beforehand, so prospective patients cannot meet the understanding requirement of informed consent. [3]
• A counter-argument holds that patients often have enough knowledge to consent, because they know they want to change their present state and that the therapy is an effective way to try. [4]
• A psychiatric ethics review adds that psychedelics remain investigational and discusses research equipoise, patient vulnerability and equity. [5]

Neither argument is test data. They show the question is open.

Consent and the design of trials

Because strong effects make it easy to tell drug from placebo, masking in psychedelic trials has been largely unsuccessful. [6] Some trials have modified consent to obscure details of the study design, which may strengthen masking but poses significant ethical risks. [6] The FDA warns of expectation bias from functional unblinding. [1] For readers of research, this means consent wording itself can interact with results. See context and expectancy.

In licensed programs

Oregon's preparation session includes review of informed consent and the client bill of rights. [7] Colorado's approved facilitator training must cover Relational Boundaries and Introduction to Physical Touch (10 hours) and Introduction to Suicide Risk (5 hours). [8] Rules differ elsewhere; this is not legal advice.

Points to look for in any consent discussion

These are things a participant may reasonably ask about, drawn from the sources above, not instructions:

• who the monitors are and what training they have (qualifications);
• what monitoring and medical backup exist (clinical monitoring);
• the rules on touch, recording, data use and complaints (professional boundaries);
• whether the treatment is approved, investigational or state-regulated (approval status).